Literature DB >> 34317795

Commentary: Extrapleural pneumonectomy during myasthenic crisis: The urge to go big or go home.

Abbas E Abbas1.   

Abstract

Entities:  

Year:  2020        PMID: 34317795      PMCID: PMC8299029          DOI: 10.1016/j.xjtc.2020.03.033

Source DB:  PubMed          Journal:  JTCVS Tech        ISSN: 2666-2507


× No keyword cloud information.
Abbas El-Sayed Abbas, MD, MS, FACS Extended resections such as extrapleural pneumonectomy for thymoma are justified only in operable patients with extensive pleural dissemination and strong expectation of complete eradication of the tumor. See Article page 168. Myasthenia gravis (MG) is an uncommon autoimmune disease related to the thymus gland that may exist both separately and in conjunction with thymoma. MG affects 30% to 50% of patients with thymoma, and thymoma is found in 10% to 30% of patients with MG. This crippling autoimmune disease usually runs a protracted progressive course. However, 10% to 20% of MG patients will develop myasthenic crises (MC), associated with respiratory failure and necessitating mechanical ventilation. Like MG, thymoma is also both rare and peculiar. Its biological behavior ranges from benign to extremely malignant, often invading local mediastinal structures, such as the innominate vein, phrenic nerve, pulmonary hilum, heart, aorta, and airways. Thymomas can also disseminate by “drop metastasis” to the pleural surfaces, much like ovarian cancer in the peritoneal cavity. Despite this, thymomas have a relatively slower progression and better prognosis than other similarly aggressive tumors. Surgical resection remains the mainstay of treatment and cure, although experienced thoracic surgeons will agree that the procedural difficulty can range from simple to challenging. This becomes important since it is well established that the most important factor affecting long-term prognosis apart from World Health Organization histological classification and Masaoka stage is completeness of resection.4, 5, 6 Therefore, surgeons must go to great lengths to achieve R0 resection. Luckily, these patients are often young and healthy and can generally tolerate heroically extensive resections when necessary. Iqbal and colleagues reported a case of extended thymectomy with extrapleural pneumonectomy (ETEPP) for recurrent thymoma invading the myocardium in a young woman with history of previous R1 resection. This patient also had respiratory failure from MC, refractory to both plasmapheresis and intravenous immunoglobulin, but, amazingly, she recovered after surgery. Although this may be the first report of ETEPP in a patient in the throes of MC, the operation has been described for pleurally disseminated thymoma (stage IVA) in several other studies.8, 9, 10, 11 Two studies compared ETEPP with lesser resections such as pleurectomy and reported superior outcomes after ETEPP (Table 1).,
Table 1

Studies of extrapleural pneumonectomy with and without pleurectomy for stage IVA thymoma

StudyProcedure2-y survival, %5-y survival, %10-y survival, %DFS, %
Wright, 200685 ETEPPNR7550
Huang et al, 200793 ETEPP9 PleurectomyNR10010010066
Ishikawa et al, 2009104 ETEPP7 PleurectomyNR7516750
Yang et al, 2011117 ETEPP100NRNR

DFS, Disease-free survival; ETEPP, extended thymectomy with extrapleural pneumonectomy; NR, not reported.

Studies of extrapleural pneumonectomy with and without pleurectomy for stage IVA thymoma DFS, Disease-free survival; ETEPP, extended thymectomy with extrapleural pneumonectomy; NR, not reported. Of course, even in young patients, ETEPP is not without significant risk. The postoperative effect of pneumonectomy in a myasthenic patient who has not yet achieved remission and is unable to physically rehabilitate may be devastating. In addition, the danger of contaminating the pneumonectomy space or the peritoneal cavity by tumor droplets may be a major risk in this indolent tumor. Far fewer studies have suggested any form of surgery, let alone ETEPP during MC. In fact, thymectomy may cause postoperative MC in 12%–34% of patients.13, 14, 15 Therefore, most authorities recommend thymectomy for nonthymomatous MG only as an elective procedure when symptoms are under control and steroids are at a minimum., These various reports of thymoma and MG surgery raise several important and controversial questions: How far should one go in resecting thymomas? Does debulking alone play a role? What is the role of surgery during MC? What is the role of neoadjuvant or adjuvant therapy? Unfortunately, owing to the rarity of these tumors, the literature does not provide sufficient evidence to answer these questions. Most of the larger series span long time periods and include different histological classifications, therapies, and surgical techniques. This rarity also precludes the conduct of prospective trials. Multicenter organization registries, such as the International Thymic Malignancy Interest Group, are important to improving our understanding of this disease. Many of the “rules” that we follow in treating advanced thymoma are based on our collective wisdom and experience. Perhaps the most crucial of these rules is the importance of achieving complete resection of the tumor whenever possible. Heroic resections are justified only after a careful evaluation of the specific tumor and patient characteristics. Such operations should be performed only in operable patients with extensive pleural dissemination and strong expectation of complete eradication of the tumor. Operating during MC on a ventilated patient may be associated with poor outcomes and cannot be considered routinely safe, especially when the planned resection is a reoperative ETEPP with myocardial resection. In such cases, it is sometimes better to not go big that day but to go home instead and wait to fight another day.
  16 in total

1.  Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis.

Authors:  Atsushi Watanabe; Toshiaki Watanabe; Takuro Obama; Tohru Mawatari; Hisayoshi Ohsawa; Yasunori Ichimiya; Noriyuki Takahashi; Katsuyuki Kusajima; Tomio Abe
Journal:  J Thorac Cardiovasc Surg       Date:  2004-03       Impact factor: 5.209

2.  Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma.

Authors:  Cameron D Wright
Journal:  Ann Thorac Surg       Date:  2006-10       Impact factor: 4.330

Review 3.  Therapy of myasthenic crisis.

Authors:  J Berrouschot; I Baumann; P Kalischewski; M Sterker; D Schneider
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  Prognostic factors and long-term results after thymoma resection: a series of 307 patients.

Authors:  J F Regnard; P Magdeleinat; C Dromer; E Dulmet; V de Montpreville; J F Levi; P Levasseur
Journal:  J Thorac Cardiovasc Surg       Date:  1996-08       Impact factor: 5.209

5.  En bloc extended total thymectomy and extrapleural pneumonectomy in Masaoka stage IVA thymomas.

Authors:  Hee Chul Yang; Yoo Sang Yoon; Hong Kwan Kim; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Jungho Han; Jhingook Kim
Journal:  J Cardiothorac Surg       Date:  2011-03-12       Impact factor: 1.637

6.  Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis.

Authors:  Giovanni Leuzzi; Elisa Meacci; Giacomo Cusumano; Alfredo Cesario; Marco Chiappetta; Valentina Dall'armi; Amelia Evoli; Roberta Costa; Filippo Lococo; Paolo Primieri; Stefano Margaritora; Pierluigi Granone
Journal:  Eur J Cardiothorac Surg       Date:  2014-02-12       Impact factor: 4.191

7.  Thymoma: a clinicopathologic study based on the new World Health Organization classification.

Authors:  Kazuo Nakagawa; Hisao Asamura; Yoshihiro Matsuno; Kenji Suzuki; Haruhiko Kondo; Arafumi Maeshima; Etsuo Miyaoka; Ryosuke Tsuchiya
Journal:  J Thorac Cardiovasc Surg       Date:  2003-10       Impact factor: 5.209

8.  Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy.

Authors:  Yoshinori Ishikawa; Haruhisa Matsuguma; Rie Nakahara; Haruko Suzuki; Akiko Ui; Tetsuro Kondo; Yukari Kamiyama; Seiji Igarashi; Kiyoshi Mori; Tetsuro Kodama; Kohei Yokoi
Journal:  Ann Thorac Surg       Date:  2009-09       Impact factor: 4.330

9.  Feasibility of multimodality therapy including extended resections in stage IVA thymoma.

Authors:  James Huang; Nabil P Rizk; William D Travis; Venkatraman E Seshan; Manjit S Bains; Joseph Dycoco; Robert J Downey; Raja M Flores; Bernard J Park; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2007-10-26       Impact factor: 5.209

Review 10.  International consensus guidance for management of myasthenia gravis: Executive summary.

Authors:  Donald B Sanders; Gil I Wolfe; Michael Benatar; Amelia Evoli; Nils E Gilhus; Isabel Illa; Nancy Kuntz; Janice M Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David P Richman; Jan Verschuuren; Pushpa Narayanaswami
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

View more
  1 in total

1.  Surgical management of locally advanced thymic neoplasms.

Authors:  Andrew Akcelik; Roman Petrov; Charles Bakhos; Abbas E Abbas
Journal:  Mediastinum       Date:  2022-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.